Industry | 制造业 | ||||||||||||||||||||||||
Company Introduction | 福建广生堂药业股份有限公司是集药品研发、生产、销售于一体的现代制药企业,GMP认证的现代化工厂,国家发改委、财政部、工信部扶持的"国家抗乙肝病毒药物高新科技产业化重点示范项目",福建省"十一五"、"十二五"规划重点工程,“国家火炬计划重点高新技术企业”。2009年广生堂拥有五项专利的国家一类新药阿甘定阿德福韦酯获福建省政府颁发的“福建省科技发明奖一等奖”、“福建省专利奖特等奖”、“福建省优秀新产品奖一等奖”、“福建省自主创新产品”。2010年12月,广生堂贺甘定拉米夫定成为入选“国家十二五科技重大专项”、“重大新药创制”类别的唯一国产拉米夫定品种。2012年年初拥有三项国家专利的恩甘定恩替卡韦成功上市,是国内首家胶囊剂型恩替卡韦。 | ||||||||||||||||||||||||
Main Business | 医药制造业。 | ||||||||||||||||||||||||
Legal Representative | 李国平 | ||||||||||||||||||||||||
Top Executives |
|
||||||||||||||||||||||||
Top 5 Shareholder |
|
||||||||||||||||||||||||
Company Secretary | 张清河 | ||||||||||||||||||||||||
Solicitors | 国浩律师(上海)事务所 | ||||||||||||||||||||||||
Auditors | 大华会计师事务所(特殊普通合伙) | ||||||||||||||||||||||||
Tel No | 0591-38265188 | ||||||||||||||||||||||||
Fax No | 0591-83052199 | ||||||||||||||||||||||||
Website | www.cosunter.com | ||||||||||||||||||||||||
zhangqinghe@cosunter.comzhangqinghe@cosunter.comzhangqinghe@cosunter.comzhangqinghe@cosunter.co | |||||||||||||||||||||||||
Company Address |
|
||||||||||||||||||||||||
Listing Date | 22/04/2015 | ||||||||||||||||||||||||
Shares Capital |
|
||||||||||||||||||||||||
EPS(RMB)* | ¥ -2.189 | ||||||||||||||||||||||||
DPS(RMB)* | -- | ||||||||||||||||||||||||
NBV Per Share(RMB)* | ¥ 3.243 | ||||||||||||||||||||||||
Market Capitalization(RMB) | 4.092B |
Only Chinese content is avaliable | |
N
/
N
: Eligible Stock for SH-HK Northbound trade (For all investors/ For institutional professional investors only)
N
: Eligible Stock for SH-HK Ex-Northbound trade (sell only)
|
|
N
/
N
: Eligible Stock for SZ-HK Northbound trade (For all investors/ For institutional professional investors only)
N
: Eligible Stock for SZ-HK Ex-Northbound trade (sell only)
|
|
* | Unadjusted Data |
Information provided by: etnet | ||
Terms and Conditions |
Risk Disclosure: |
The prices of securities may fluctuate, sometimes dramatically. The price of a security may move up or down, and may become valueless. It is as likely that losses will be incurred rather than profit made as a result of buying and selling securities. The information is for reference only, it does not constitute any offer, solicitation, recommendation, comment or any guarantee to the purchase or sale of any investment product or service. Customers should not make any investment decisions based on this information alone. |
Disclaimer: |
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information. |